Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients

Journal of Clinical Microbiology

Volumn 50, Issue 3, 2012, Pages 823-830

  Bergeron, Anne ^a   Porcher, Raphaël ^b   Menotti, Jean ^a   Poirot, Jean Louis ^c   Chagnon, Karine ^a   Vekhoff, Anne ^a,c   Cornet, Muriel ^a,g   Isnard, Françoise ^c   Raffoux, Emmanuel ^a   Brethon, Benoit ^a   Lacroix, Claire ^a   Touratier, Sophie ^d   Latgé, Jean Paul ^e   Bouges Michel, Claire ^f   Tazi, Abdellatif ^a   Derouin, Francis ^a   Ribaud, Patricia ^a   Sulahian, Annie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e INSTITUT PASTEUR   (France)

^f UNIVERSITÉ PARIS 13   (France)

^g HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FUNGAL DNA; FUNGUS ANTIBODY; GALACTOMANNAN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DNA DETERMINATION; FEMALE; FOLLOW UP; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; BIOLOGICAL MARKERS; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INVASIVE PULMONARY ASPERGILLOSIS; LONGITUDINAL STUDIES; MALE; MANNANS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; STEROIDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857398575     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00750-11     Document Type: Article

References (30)

1. Anaissie EJ. 2007. Trial design for mold-active agents: time to break the mold-aspergillosis in neutropenic adults. Clin. Infect. Dis. 44:1298-1306. (Pubitemid 46717291)
2. Ascioglu S, et al. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14. (Pubitemid 33152659)
3. Boutboul F, et al. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin. Infect. Dis. 34:939-943. (Pubitemid 34229762)
4. Caillot D, et al. 2001. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J. Clin. Oncol. 19:253-259. (Pubitemid 32063503)
5. Caillot D, et al. 2010. Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: a useful tool for diagnosis and assessment of outcome in clinical trials. Eur. J. Radiol. 74:e172-e175.
6. Challier S, Boyer S, Abachin E, Berche P. 2004. Development of a serum-based TaqMan real-time PCR assay for diagnosis of invasive aspergillosis. J. Clin. Microbiol. 42:844-846. (Pubitemid 38222678)
7. Cordonnier C, et al. 2009. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin. Microbiol. Infect. 15:81-86.
8. Cornely OA, et al. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44:1289 -1297.
9. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
10. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
11. Herbrecht R, et al. 2010. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. 45:1227-1233.
12. Hope WW, Walsh TJ, Denning DW. 2005. Laboratory diagnosis of invasive aspergillosis. Lancet Infect. Dis. 5:609-622. (Pubitemid 41383906)
13. Hummel M, et al. 2010. Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial. Eur. J. Haematol. 85:164-169.
14. Kami M, et al. 2001. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin. Infect. Dis. 33:1504-1512. (Pubitemid 34246144)
15. Koo S, Bryar JM, Baden LR, Marty FM. 2010. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J. Clin. Microbiol. 48:1255-1260.
16. Maertens J, et al. 2009. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115:355-362.
17. Miceli MH, Maertens J, Buve K. 2007. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 110:112-120. (Pubitemid 46986424)
18. Miceli MH, et al. 2008. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 46:1412-1422. (Pubitemid 351589942)
19. Millon L, et al. 2005. Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. J. Clin. Microbiol. 43:5097-5101. (Pubitemid 41484011)
20. Neofytos D, et al. 2010. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl. Infect. Dis. 12:220-229.
21. Nivoix Y, et al. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47:1176-1184.
22. Nucci M, et al. 2010. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin. Infect. Dis. 51:1273-1280.
23. Sarfati J, et al. 2006. Recombinant antigens as diagnostic markers for aspergillosis. Diagn. Microbiol. Infect. Dis. 55:279-291. (Pubitemid 44144515)
24. Segal BH, et al. 2008. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin. Infect. Dis. 47:674-683.
25. Shaukat A, et al. 2005. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 159:181-188. (Pubitemid 40633920)
26. Steinbach WJ, Juvvadi PR, Fortwendel JR, Rogg LE. 2011. Newer combination antifungal therapies for invasive aspergillosis. Med. Mycol. 49:S77-S81.
27. Stynen D, Goris A, Sarfati J, Latge JP. 1995. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J. Clin. Microbiol. 33:497-500.
28. Wingard JR, et al. 2010. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116:5111-5118.
29. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. 2008. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 112:2309-2312. (Pubitemid 351628643)
30. Woods G, et al. 2007. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 110:830-834. (Pubitemid 47257661)